ies have documented the anti-hyperglycemic and antihyperlipidemic activities of ginsenosides [12] [13] [14] [15] [16] [17] . To date, more than 60 ginsenosides have been identified in different parts of the ginseng plant, and extracts of ginseng roots, rootlets, berries, and leaves have shown pharmacological activities such as islet protection, insulin sensitization, and anti-hyperglycemia, anti-obesity, and antioxidant effects [18] [19] [20] [21] [22] [23] .
AMP-activated protein kinase (AMPK) is a serinethreonine kinase that is activated following a rise in the intercellular AMP:ATP ratio [24] . Recently, AMPK has emerged as an attractive target molecule for the treatment of metabolic disorders, including obesity and type 2 diabetes [25] . The amelioration of hyperglycemia and hyperlipidemia by several flavonoids is thought to be mediated via AMPK activation [26, 27] . However, it is not known whether the beneficial effects of the ginseng leaf on high fat diet-induced hyperglycemia and hyperlipidemia are attributable to AMPK activation. Here, we investigated the anti-hyperglycemic and antihyperlipidemic effects of ginseng leaf and the potential mechanisms underlying these actions in C57BL/6J mice fed a high fat diet.
MATERIALS AND METHODS

Preparation of ginseng leaf extract
Ginseng leaves were dried in the shade for 1 week and extracted by boiling in 70% ethanol for 5 h. The solution (ginseng leaf extract� GLE) was filtered and evaporated under vacuum to obtain a powder.
Animals and diets
Six-week-old C57BL/6J mice were purchased from Orient Bio (Seoul, Korea) and acclimatized to the laboratory environment for 1 week before the experiment. The mice were allowed free access to water and food and were housed under conditions of constant room temperature (22±2°C) and humidity (50±10%) with an automatic 12 h light:12 h dark cycle. The experimental protocol was approved by the �nstitutional Animal Ethics Committee of Kyung Hee University. The mice were randomly divided into four groups of six mice each: normal control (Con), high fat diet (HFD), HFD+GLE at 250 mg/kg (G250), and HFD+GLE at 500 mg/kg (G500). Control mice were allowed free access to the regular diet (�on) or HFD� �n the GLE-treated groups� mice were allowed free access to a HFD for 6 weeks and were then orally administered GLE once daily for 8 weeks. The composition of the experimental diet (Table   1 ) was based on the HFD 45% cal semi-synthetic diet. Body weight was measured once a week during the experiment.
Determination of serum parameters
At the end of the experimental period, blood samples were collected and the levels of plasma glucose, insulin, triglycerides (TG)� total cholesterol (T�)� non-esterified fatty acids (NEFA), and leptin were measured. Plasma glucose concentrations were determined using the glucose oxidase method (Asan Pharmaceutical Co., Seoul, Korea); plasma insulin concentrations, using a mouse insulin enzyme immunoassay kit (Sibayagi, Gunma, Japan); plasma TG and TC concentrations, using commercially available kits (Asan Pharmaceutical); plasma NEFA levels, using the enzymatic colorimetric method (Eiken, Tokyo, Japan); and leptin levels, using a mouse leptin enzyme immunoassay kit (Linco Research, St. Charles, MO, USA).
Histological analysis
Liver tissue was fixed in 10% neutral-buffered formalin� embedded in paraffin� and sectioned at a 5 μm thickness (Leica, Wetzlar, Germany). The sections were stained with hematoxylin-eosin for microscopic assess- http://ginsengres.org ment (Olympus, Tokyo, Japan).
Western blot analysis
After the mice were sacrificed� the liver was immediately removed, instantly soaked in liquid nitrogen, and stored at -70°C. Protein extracts were prepared using a protein extraction kit (�ntron Biotechnology �nc�� Seoul� Korea)� Lysates (40 μg) were electrophoresed in an 8% SDS-polyacrylamide gel, and the separated proteins were electroblotted onto a nitrocellulose membrane. The membrane was incubated for 1 hr at room temperature in a blocking solution of Tris-buffered saline plus Tween 20 (TBST) containing 5% skim milk (w/v), followed by incubation overnight at 4°C with a 1:2,000 dilution of antibody against AMPK, phospho-AMPK, acetyl-CoA carboxylase (ACC), phospho-ACC (Cell Signaling, Beverly� MO� USA)� or β-actin (Santa �ruz Biotechnology, Santa Cruz, CA, USA). After four washes in 0.1% TBST, the membrane was incubated with a 1:3,000 dilution of horseradish peroxidase-conjugated goat antirabbit �gG or donkey anti-rabbit �gG antibody (Santa Cruz Biotechnology) for 1 hr at room temperature. The membrane was washed four times in TBST, and immunoreactive protein bands were visualized by enhanced chemiluminescence (Amersham, Uppsala, Sweden).
RNA preparation and RT-PCR
Total mRNA was isolated from mouse livers using an Easy-Blue kit (�ntron Biotechnology) according to the manufacturer's instructions. From each sample, total RNA (10 μg) from each sample was reverse transcribed into cDNA using Moloney murine leukemia virus transcriptase and oligo(dT)15 primer (Promega, Madison, W�� USA)� P�R was performed using the following specific sense and anti-sense primer sets: sterol regulatory element-binding protein 1a (SREBP1a)� 5′-G�G �TA ��G GT� TT� TAT �A-�′ and 5′-TG� TG� �AA AAG A�A AGG G-�′; fatty acid synthase (FAS)� 5′-GAT ��T GGA A�G AGA A�A �-�′ and 5′-AGA �TG TGG AA� A�G GTG GT-�′; sterol-�oA desaturase 1 (S�D1)� 5′-�GA GGG TTG GTT GTT GAT �TG T-�′ and 5′-ATA G�A �TG TTG G�� �TG GA-�′; glycerol-�-phosphate acyltransferase (GPAT)� 5′-GGT AGT GGA TA� T�T GT� GT� �A-�′ and 5′-�AT �AG �AA �AT �AT T�G GT-�′; peroxisome proliferator-activated receptor-� (PPAR-�)� 5′-��� TGA A�A T�G AGT GT� GA-�′ and 5′-�TT G�� �AG AGA TTT GAG GT� �T-�′; �D��� 5′-T��T�T GA� ATT TG� AGG T�T AT�-�′ and 5′-GTG AAT ��A GTT ATG GGT T�� A�-�′; phosphoenolpyruvate carboxykinase (PEP�K)� 5′-ATG ��T ��T �AG �TG �AT A-�′ and 5′-TTA �AT �TG G�T GAT T�T �TG TT-�′; and cyclophilin (�PN)� 5′-ATG GT� AA� ��� A�� GTG-�′ and 5′-TTA GAG TTG T�� A�A GT� GGA GA-�′� �PN was amplified as a control gene� P�R was performed at 95°C for 5min, 95°C for 30 sec, 57°C for �0 sec� 72°� for �0 sec� and amplified for �0 cycles� PCR was performed at of 95°C for 30 s; 51°C (CD36), 55°� (SREBP1a� FAS� PPAR-�� PEP�K� �PN)� or 57°C (SCD1, GPAT) for 30 s; and 72°C for 1 min, with a final extension at 72°� for 10 min� The P�R products were electrophoresed in a 1% agarose gel and visualized by ethidium bromide staining (0�5 μg/mL)� Scanning densitometry was performed with an �-MAX gel image analysis system (Core-Bio, Seoul, Korea).
Statistical analysis
The results are expressed as means±SEM. Differences between groups were analyzed using Student's t-test. Statistical significance was considered for p<0.05. Table 2 shows the effects of GLE on body weight gain, food intake� and feed efficiency in HFD-induced obese mice treated for 8 weeks. Compared with the HFD control group, the G250 and G500 groups had 3.27% and ��85% lower final body weights (p<0.05), respectively. The G500 group also showed lower food intake and significantly decreased feeding efficiency (p<0.05) as compared with the HFD group. Table 3 shows the effects of GLE on metabolic parameters in HFD-induced obese mice. Plasma glucose levels were significant decreased by 18.2% (p<0.01) and 22.6% (p<0.01) in the G250 and G500 groups, respectively, compared with the level in the HFD control group, and plasma insulin levels were 51.7% (p<0.001) and 52.9% (p<0.001) lower in the G250 and G500 groups as compared with the HFD control. The lower plasma glucose and insulin levels resulted in markedly lower insulin resistance index (HOMA-�R) values in the GLE-treated groups as compared with the HFD control, 60.9% lower (p<0.001) in the G250 group and 63.6% lower (p<0.001) in the G500 group. The plasma TG, T�� and NEFA levels were significantly lower� by �0�5% (p<0.001), 17.8% (p<0.001), and 36.8% (p<0.001), respectively, in the G500 group as compared with the HFD group.
RESULTS
Effects on body weight and food intake
Effects on metabolic parameters
Histological observations
Histological analysis revealed significantly fewer lipid droplets in the livers from GLE-treated mice than in the HFD control livers (Fig. 1A) .
Effect on AMPK activation
AMPK plays a key role in regulating carbohydrate and lipid metabolism and a potential therapeutic target for treatment of metabolic diseases [28] . The activation of hepatic AMPK leads to increased fatty acid oxidation and ketogenesis along with the simultaneous inhibition of hepatic fatty acids, TG, lipogenesis, cholesterol synthesis, and glucose production [28] [29] [30] [31] . We examined whether GLE activates AMPK via phosphorylation in the liver. As shown in Fig. 1B , GLE-treated mice had significantly higher levels of phosphorylated AMPK and ACC than HFD control mice.
Effects on gene expression related to lipogenesis, lipolysis, and gluconeogenesis
The expression of genes involved in lipogenesis, lipolysis and gluconeogenesis were examined by RT-PCR. As shown in Fig. 1C , GLE did not affect the expressions of SREBP1a, FAS, SCD1, and GPAT, which are all associated with TG synthesis (Fig. 1C) . However, the expression levels of the fatty acid transport protein CD36 gene and the lipolysis-related PPAR-� gene were increased in GLE-treated mice� �n addition� the expression of PEPCK, a rate-limiting enzyme of the gluconeogenesis pathway, was decreased in GLE-treated mice as compared with the HFD control mice.
DISCUSSION
Ginseng is a well-known medicinal plant that has been used in traditional oriental medicine for several thousand years� �n traditional �hinese medicine� ginseng root has been used more often than other plant parts; however, it is quite costly. Other parts of the ginseng plant such as berries and leaves could be harvested along with the root to yield additional herbal material and to improve the cost-effectiveness of ginseng cultivation [32] . However, one issue of concern regarding the use of ginseng as a therapeutic agent is its marginal anti-diabetic effects compared with commercially available oral hypoglycemics� To develop a more efficacious anti-diabetic agent from ginseng, GLE was considered. GLE has recently been reported to possess hypoglycemic activity [32,33], Table 3 . Effects of ginseng leaf extract on metabolic parameters in blood Con HFD G250 G500
Blood glucose (mM) 15.7±0.5 21.5±0. 5 1) 19.0±0. 9 2) 17.7±0. 5 1) �nsulin (U/mL) 60.2±12.3 235.6±34.1 1) 113.9±14.1 1) 110.9±13. 8 1) HOMA-�R 42.3±8.9 223.7±30.8 1) 98.2±16.2 1) 87.5±10.9 1) Triglycerides (mg/dL) 50.1±3.3 87.1±3.7 1) 67.3±3.5 2) 60.5±2.5 1) Cholesterol (mg/dL) 120.3±4.7 188.2±2.7 1) 161.3±4.1 1) 154.7±2.5 1) Leptin (ng/mL) 2.1±0.3 13.7±1. 6 1) 13.8±0.9 11.4±1.1
NEFA (μEq/L) 1151.2±63.0 1700.2±62.9 1) 1048.8±46.4 1) 1074.0±61.2
1)
Values represent the mean±SE (n=6). Plasma parameters were analyzed in plasma samples obtained from blood of 12 hr fasted mice. Homeostasis Model Assessment was used to calculate an index of insulin resistance as insulin (U/mL) x glucose (mM)/22. although the mechanisms underlying its beneficial effects on high fat diet-induced diabetes have not been identified� �n the present study� we investigated the protective effects of GLE against HFD-induced hyperglycemia in C57Bl/6J mice and found that GLE prevented HFD-induced diabetes via AMPK activation. Obesity is a well-recognized risk factor for type 2 diabetes, especially when combined with other known risk factors, and reduction of the risk for type 2 diabetes through weight management has been an important therapeutic goal� �n the present study� GLE prevented body weight gain and significantly decreased plasma glucose and insulin levels in HFD-induced obese mice. As a result of decreased plasma glucose and insulin levels, the HOMA-�R values in the GLE groups were also significantly decreased as compared with the value in the HFD group� �n addition� the levels of plasma TG� T�� NEFA� and leptin were all significantly lower in the GLEtreated group than in the HFD group. These results suggest that GLE may have beneficial effects on improving insulin resistance and hyperlipidemia induced by HFD. Histological analysis revealed a significantly lower number of lipid droplets in the livers from GLE-treated mice as compared with HFD mice (Fig. 1A) . Taken together, these results demonstrate that GLE has strong effects on obesity-related hyperglycemia and hyperlipidemia.
AMPK is a heterotrimeric serine/threonine kinase that is widely expressed in a variety of organs, including the liver. Numerous studies have described the effects of AMPK activation on liver metabolism [34, 35] . Two of the classical therapeutic targets of the system are ACC and 3-hydroxy-3-methylglutaryl-CoA reductase, which catalyze the key regulatory steps in fatty acid and sterol synthesis, respectively. The overall effects of AMPK activation in the liver include decreases in fatty acid, triglyceride, and sterol synthesis, and increases in fatty acid oxidation and ketogenesis [29-�1] � �n the present study, higher levels of phosphorylated AMPK and ACC were seen in GLE-treated mice as compared with HFD control mice. This result may elucidate the mechanism by which GLE promotes fatty acid oxidation and inhibits TG accumulation, thus enhancing insulin sensitivity.
�t has been reported that AMPK improves a decreased ATP:AMP ratio [24] . When AMPK is activated, it inhibits lipogenic enzymes through the inhibition of SREBP1 transcriptional activity [36] . Numerous studies have indicated that SREBP1s play a key role in triglyceride synthesis by regulating lipogenesis genes such as FAS, SCD1, and GPAT� Moreover� lipolysis genes such as PPAR-� and �D�� also participate fatty acid oxidation [�0��7]� �n the present study, GLE did not affect the expression of SREBP1�� FAS� S�D1� and GPAT� which are all associated with TG synthesis, whereas it increased the expression of the fatty acid uptake-lipolysis-related genes �D�� and PPAR-�� �nterestingly� the expression of PEPCK, a rate-limiting enzyme in the gluconeogenesis pathway, was markedly decreased in GEL-treated mice as compared with the HFD control mice. Based on these results, we conclude that GLE stimulated fatty acid β-oxidation via AMPK activation and A�� inactivation� and increased the expression of genes associated with lipolysis (i�e�� �D��� PPAR-�)� thereby stimulating fatty acid oxidation and decreased triglyceride content in the liver. Furthermore, through AMPK activation, GLE reduced hepatic glucose production by inhibiting PEPCK expression. As a result, GLE intercepted triglyceride amassment and ameliorated the insulin resistant status, subsequently decreasing fasting glucose levels.
�n summary� we conclude that GLE prevents HFDinduced hyperglycemia and hyperlipidemia via AMPK activation in C57BL/6J mice and that GLE may be a potential therapeutic agent for type 2 diabetes or dyslipidemia.
